Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

CMS' 2012 Budget Looks To Biosimilars, Ban On Brand/Generic Deals To Offset Costs

Feb 14 2011

• By Cathy Kelly

Related Content

FTC's Reverse Settlement Campaign May Depend On Congress After Another Court Loss

Feb 24 2010

FTC Rulemaking Could Be Next (And Last?) Attempt To Curb "Pay-For-Delay"

Dec 06 2010

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window